En août 2023, dans le cadre du Groupement d’accès aux technologies contre la COVID-19 (C-TAP) de l’OMS, le Medicines Patent Pool a signé une licence de portée mondiale avec le Conseil supérieur de la recherche scientifique espagnol (CSIC) pour un candidat-vaccin fondé sur une souche virale fortement atténuée, le MVA (Modified Vaccinia Ankara virus) ; celle-ci a été modifiée de manière à exprimer une protéine Spike (S) de pleine longueur du SARS-CoV-2, optimisée pour les codons humains et stabilisée en conformation pré-fusion.

MPP invites interested developers anywhere in the world to express their interest in obtaining a sublicence for this technology by submitting an e-mail to C-TAPvaccines@medicinespatentpool.org  providing as much detail as possible as to what the developer intends to do with a sublicence.

Principales caractéristiques
Aim of the Licence To facilitate the manufacture and commercialisation of COVID-19 vaccine around the world.
Products Any product that is covered by the Patents or uses the know-how or material.
Know‐how CSIC to provide all necessary know-how and materials (including the premaster virus seed for MVA-CoV2-S(3P) and unmodified derivatives) to the licensees.

The licence does not include any Know-How held by Biofabri.

Field of use COVID-19 vaccine
Territory Worldwide
Scope of the grant Non-exclusive right to grant sublicences to develop the licensed patents/know-how/material into licensed products, and to commercialise licensed products.
  • royalty-free for low and middle-income countries.
  • 5% for high-income countries, where there is a Patent granted and in force.
  • 5% for high-income countries, where no Patent but if the licensee has used the know-how or material.
Liste des pays